NeuroScientific Biopharmaceuticals Limited engages in the research and development of novel peptide-based pharmaceutical products. The company is involved in the development of therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative Alzheimer's disease, multiple scierosis, glaucoma, optic nerve atrophy, and other diseases. The company was incorporated in 2002 and is based in Cottesloe, Australia.